U.S. rethinks timing of biotech crackdown, easing pressure on WuXi family
The latest draft of a U.S. biosecurity law would give drug companies until 2032 to cut their ties with Chinese contract suppliers, allowing WuXi companies time to focus on Europe…
2269.HK
2359.HK
2268.HK
Recent Articles
U.S. rethinks timing of biotech crackdown, easing pressure on WuXi family
2269.HK
2359.HK
2268.HK
RELATED ARTICLES
-
WuXi AppTec mulls gene unit sale to soften U.S. legal blow
2359.HK 603259.SHG
-
WuXi AppTec posts lower profits but avoids more share price pain
2359.HK 603259.SHG
- CHINA BULLETIN: Manufacturing Déjà Vu
- CHINA BULLETIN: U.S. Ratchets Up Strategic Tariffs
-
China-focused Tigermed staves off biopharma gloom
3347.HK 300347.SHE
Discover hidden China stock gems in our weekly newsletter